Bevifimod
Modify Date: 2024-07-17 15:35:27
Bevifimod structure
|
Common Name | Bevifimod | ||
|---|---|---|---|---|
| CAS Number | 2223113-32-2 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of BevifimodBevifimod (PRTX-100) is a highly purified form of Staphylococcal protein A (SpA). Bevifimod can be used for idiopathic thrombocytopenic purpura (ITP) research[1][2]. |
| Name | Bevifimod |
|---|
| Description | Bevifimod (PRTX-100) is a highly purified form of Staphylococcal protein A (SpA). Bevifimod can be used for idiopathic thrombocytopenic purpura (ITP) research[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Bevifimod（PRTX-100；250、25 和 2.5 ng/mL；48 小时）抑制外周血单核细胞 (PBMC) 中人单核细胞对 W632 调理血小板的吞噬作用[1]。 |
| In Vivo | Bevifimod (PRTX-100; 2.5-250 μg/kg; i.v.; once every two weeks; for 4 weeks) increases platelet counts to within normal levels within 1-2 weeks and none of the mice died[2]. Animal Model: SCID mice bearing immune thrombocytopenia (ITP)[2] Dosage: 2.5 μg/kg, 25 μg/kg, 250 μg/kg Administration: i.v.; once every two weeks; for 4 weeks Result: Raised platelet counts in a well-established murine model of ITP. |
| References |
[1]. ChrisYatkoBS, et al. PRTX-100 Inhibits Platelet Phagocytosis In Vitro. Blood (2006) 108 (11): 1081. |
| No Any Chemical & Physical Properties |